BMRN
Income statement / Annual
Last year (2025), Biomarin Pharmaceutical Inc.'s total revenue was $3.22 B,
an increase of 12.87% from the previous year.
In 2025, Biomarin Pharmaceutical Inc.'s net income was $348.90 M.
See Biomarin Pharmaceutical Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$3.22 B |
$2.85 B |
$2.42 B |
$2.10 B |
$1.85 B |
$1.86 B |
$1.70 B |
$1.49 B |
$1.31 B |
$1.12 B |
| Cost of Revenue |
$736.83 M
|
$580.24 M
|
$532.06 M
|
$503.02 M
|
$470.52 M
|
$524.27 M
|
$359.47 M
|
$315.26 M
|
$241.79 M
|
$209.62 M
|
| Gross Profit |
$2.48 B
|
$2.27 B
|
$1.89 B
|
$1.59 B
|
$1.38 B
|
$1.34 B
|
$1.34 B
|
$1.18 B
|
$1.07 B
|
$907.23 M
|
| Gross Profit Ratio |
0.77
|
0.8
|
0.78
|
0.76
|
0.75
|
0.72
|
0.79
|
0.79
|
0.82
|
0.81
|
| Research and Development Expenses |
$921.93 M
|
$747.18 M
|
$746.77 M
|
$649.61 M
|
$628.79 M
|
$628.12 M
|
$715.01 M
|
$696.33 M
|
$610.75 M
|
$661.91 M
|
| General & Administrative Expenses |
$1.15 B
|
$532.30 M
|
$404.00 M
|
$372.90 M
|
$354.30 M
|
$334.30 M
|
$298.70 M
|
$280.20 M
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$124.00 M
|
$476.70 M
|
$488.40 M
|
$450.30 M
|
$405.10 M
|
$403.40 M
|
$382.20 M
|
$324.20 M
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$1.28 B
|
$1.01 B
|
$892.40 M
|
$823.20 M
|
$759.40 M
|
$737.70 M
|
$680.90 M
|
$604.40 M
|
$554.34 M
|
$476.59 M
|
| Other Expenses |
-$248.00 M
|
$33.28 M
|
$62.22 M
|
-$40.76 M
|
$69.91 M
|
$13.81 M
|
$49.13 M
|
-$1.21 M
|
-$78.53 M
|
$572.17 M
|
| Operating Expenses |
$1.95 B
|
$1.79 B
|
$1.70 B
|
$1.43 B
|
$1.46 B
|
$1.38 B
|
$1.45 B
|
$1.30 B
|
$1.09 B
|
$1.71 B
|
| Cost And Expenses |
$2.69 B
|
$2.37 B
|
$2.23 B
|
$1.94 B
|
$1.93 B
|
$1.90 B
|
$1.80 B
|
$1.61 B
|
$1.33 B
|
$1.92 B
|
| Interest Income |
$74.90 M
|
$74.88 M
|
$58.34 M
|
$18.03 M
|
$10.48 M
|
$16.61 M
|
$22.75 M
|
$22.83 M
|
$14.85 M
|
$7.49 M
|
| Interest Expense |
$10.90 M
|
$12.67 M
|
$17.34 M
|
$15.97 M
|
$15.34 M
|
$29.31 M
|
$23.46 M
|
$43.66 M
|
$42.71 M
|
$39.50 M
|
| Depreciation & Amortization |
$79.56 M
|
$96.43 M
|
$104.39 M
|
$101.97 M
|
$108.04 M
|
$105.17 M
|
$105.30 M
|
$95.67 M
|
$87.86 M
|
$96.91 M
|
| EBITDA |
$572.94 M |
$650.53 M |
$306.77 M |
$265.36 M |
$47.43 M |
$83.66 M |
$31.92 M |
-$3.37 M |
$90.97 M |
-$698.01 M |
| EBITDA Ratio |
0.18
|
0.23
|
0.13
|
0.13
|
0.03
|
0.04
|
0.02
|
-0
|
0.07
|
-0.62
|
| Operating Income Ratio |
0.17
|
0.17
|
0.08
|
0.08
|
-0.04
|
-0.02
|
-0.06
|
-0.08
|
-0.01
|
-0.72
|
| Total Other Income/Expenses Net |
-$51.00 M
|
$57.55 M
|
$2.79 M
|
-$11.40 M
|
$6.99 M
|
-$5.56 M
|
$5.65 M
|
-$19.18 M
|
-$21.18 M
|
-$27.62 M
|
| Income Before Tax |
$482.48 M
|
$541.76 M
|
$188.56 M
|
$149.58 M
|
-$75.35 M
|
-$49.00 M
|
-$94.81 M
|
-$142.71 M
|
-$35.88 M
|
-$831.05 M
|
| Income Before Tax Ratio |
0.15
|
0.19
|
0.08
|
0.07
|
-0.04
|
-0.03
|
-0.06
|
-0.1
|
-0.03
|
-0.74
|
| Income Tax Expense |
$133.58 M
|
$114.90 M
|
$20.92 M
|
$8.02 M
|
-$11.27 M
|
-$903.03 M
|
-$70.96 M
|
-$65.49 M
|
$81.17 M
|
-$200.84 M
|
| Net Income |
$348.90 M
|
$426.86 M
|
$167.65 M
|
$141.56 M
|
-$64.08 M
|
$854.03 M
|
-$23.85 M
|
-$77.21 M
|
-$117.04 M
|
-$630.21 M
|
| Net Income Ratio |
0.11
|
0.15
|
0.07
|
0.07
|
-0.03
|
0.46
|
-0.01
|
-0.05
|
-0.09
|
-0.56
|
| EPS |
1.82 |
2.25 |
0.89 |
0.76 |
-0.35 |
4.75 |
-0.13 |
-0.44 |
-0.67 |
-3.8 |
| EPS Diluted |
1.8 |
2.21 |
0.88 |
0.75 |
-0.35 |
4.53 |
-0.13 |
-0.44 |
-0.67 |
-3.79 |
| Weighted Average Shares Out |
$191.79 M
|
$190.03 M
|
$187.83 M
|
$185.27 M
|
$182.85 M
|
$180.80 M
|
$179.04 M
|
$177.06 M
|
$174.43 M
|
$165.99 M
|
| Weighted Average Shares Out Diluted |
$197.39 M
|
$196.71 M
|
$191.60 M
|
$188.96 M
|
$182.85 M
|
$191.68 M
|
$179.04 M
|
$177.27 M
|
$174.43 M
|
$166.22 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
